Wanting Qiang

Jul 25, 2024 | jamanetwork.com | Wanting Qiang |Jia Liu |Jin Liu |Juan Du

Key PointsQuestion  What are the safety, pharmacokinetic, and survival outcomes of B-cell maturation antigen (BCMA)/CD19 dual-targeting chimeric antigen receptor (CAR) T-cell therapy in individuals with high-risk newly diagnosed multiple myeloma who receive it as a frontline treatment? Findings  In this single-arm, open-label phase 1 cohort study including 19 patients in the efficacy analysis, all patients (100%) achieved stringent complete responses and minimal residual disease negativity.